Deleobuvir

Research use only, not for human use.

Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity.

Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity; demonstrates subgenomic antiviral activity against GT1b and GT1a with EC50 of 11 and 23 nM in cell-based replicon assays; shows weak or no inhibition in specificity assays that include poliovirus RdRp, mammalian DdRp II, and DNA polymerase α, β, and γ; displays good antiviral potency and tolerability in early clinical trials of short-term treatment either as a single agent or in combination with pegylated IFN-α2a/ribavirin in HCV GT1 patients.HCV Infection Phase 3 Clinical.

——

——

BI 207127 | BI207127 | BI-207127

Microbiology/Virology

HCV

HCV

Infection

HCV Infection

863884-77-9

653.581

C34H33BrN6O3

>98% (HPLC)

——

O=C(O)/C=C/C1=CC=C2N=C(C3(NC(C4=CC5=C(C=C4)C(C6CCCC6)=C(C7=NC=C(Br)C=N7)N5C)=O)CCC3)N(C)C2=C1

(E)-3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid

(-20℃)

With Ice Pack

≥ 2 years